Wang Xiaodong (Director) sold $11.3M of stock, under a pre-arranged trading plan
SEC Form 4
Beone Medicines Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
~$160
Valuation models combined (2)
Base case. Range ~$130–$230. Weighted average of 2 models (forward price-to-earnings vs peers, forward price-to-sales vs peers).
Price vs value
No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.
Beone Medicines Ltd. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders0 buying, 12 selling0 purchases and 213 sales by directors and officers, last 12 monthsInsider trades
- Funds164 adding, 109 cuttingOf 42 active managers that changed their stake, 27 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 26% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
- Estimates rising. Analysts' consensus for next year's earnings per share has risen 7.9% over 90 days.
Things to watch
- Insiders selling. 12 insiders sold $391M of stock over the past 365 days and none bought (96% under pre-set trading plans).
Latest results
- Earnings per share
- $2.05 against an average estimate of $1.63: beat by 25.7%
- Share reaction
- -1.0% in the first session after the results on August 26, 2026, against +0.7% for the S&P 500
- Next report
- November 5, 2026; average EPS estimate $1.88
Price chart
- 1 day-2.4%
- 1 week-2.6%
- 1 month+0.9%
- This year+18.9%
- 1 year+16.4%
- 5 years-3.3%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 26, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Insider trade
- Insider trade
Wang Xiaodong (Director) sold $10.9M of stock, under a pre-arranged trading plan
SEC Form 4 - Insider trade
Wang Xiaodong (Director) sold $7.6M of stock, under a pre-arranged trading plan
SEC Form 4 - Results
Beone Medicines Ltd. reported results
SEC 8-KRead source ↗ - Results
Beone Medicines Ltd. reported results
SEC 8-KRead source ↗
Valuation models
We value Beone Medicines Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 9.1%: the 10-year Treasury yield (4.9%) plus a beta of 0.91 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | — | Does not apply: no revenue, margin or share count to start from |
| Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$130 ~$120–$240 | Included |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$230 ~$230–$880 | Included, half weight |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$160 ~$130–$230 | 2 models |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Beone Medicines Ltd. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 5, 2026, before the open. Analysts expect revenue of $1.8bn and EPS of $1.88 (range $1.56 to $2.24) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | $7.64 | +202% | $6.8bn | +27% |
| Next | $10.45 | +37% | $7.8bn | +15% |
Next year's EPS estimate has moved +7.9% in 90 days, across 16 analysts.
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +16.6% on 90 days ago. In the last 30 days, 3 analysts raised Beone Medicines Ltd.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | $6.55 | $9.68 |
| 60 days ago | $7.60 | $10.28 |
| 30 days ago | $7.60 | $10.32 |
| 7 days ago | $7.64 | $10.25 |
| Now | $7.64 | $10.45 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | $1.63 | $2.05 | +25.7% |
| Mar 2026 | $0.81 | $1.96 | +143.2% |
| Dec 2025 | $1.30 | $0.58 | −55.3% |
| Sept 2025 | $0.86 | $1.09 | +27.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 2.2% of tradable shares
- Days to cover
- 4.72 at average volume
- Short interest, 1 month
- +5% to October 15, 2026
- Held by institutions
- 34% of shares
- Held by insiders
- 17.3% of shares
- Employees
- 12,000 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| ONC | +5% | −19% | −18% | +2% | +65% | +19% |
| Industry peers (median) | −36% | −57% | −17% | −29% | −5% | −27% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| ONC | 33% | 50% | 42% | 42% | 58% | 46% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| ONC | −38% | −55% | −42% | −29% | −26% | −30% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since February 3, 2016: 70% from September 17, 2021 to May 11, 2022. Getting back needed a 233% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $260.27 – $386.46
- From 52-week high
- −6.5%
- vs 50-day average
- −0.4%
- vs 200-day average
- +11.2%
- Volatility (1 year)
- 35%
- Beta vs S&P 500
- 0.80
Share price after results
- Next day
- 6 up, 6 down typical move ±4.4%
- After a week
- 7 up, 5 down typical move ±7.8%
- After a month
- 7 up, 5 down typical move ±8.2%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 26, 2026 | −1.0% | +0.7% | −3.9% | −4.1% |
| August 5, 2026 | +2.1% | −0.4% | +11.2% | +12.3% |
| May 6, 2026 | +6.6% | +1.1% | +6.4% | −9.2% |
| April 14, 2026 | +4.7% | +2.0% | +2.2% | +3.6% |
| February 26, 2026 | −10.0% | −1.0% | −16.8% | −19.6% |
| November 6, 2025 | −0.4% | −1.0% | +14.6% | +1.6% |
| August 29, 2025 | +11.4% | −1.3% | +16.3% | +14.3% |
| August 6, 2025 | −2.9% | +0.7% | +0.1% | +11.3% |
| May 7, 2025 | −2.4% | +1.1% | −9.0% | +5.8% |
| April 28, 2025 | +2.0% | +0.7% | +3.8% | −1.8% |
| February 27, 2025 | +4.9% | −0.1% | −0.8% | +3.2% |
| November 12, 2024 | −4.7% | −0.3% | −8.4% | −12.1% |
Fundamentals
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $5.3B | 98.9% | ▲ 39.8% |
| Collaboration | $61M | 1.1% | ▲ 98.6% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $2.9B | 53.9% | ▲ 47.1% |
| China | $1.7B | 31.4% | ▲ 19.0% |
| Europe | $611M | 11.4% | ▲ 68.6% |
| All Other Countries Except China United States of America and Switzerland | $172M | 3.2% | ▲ 118.0% |
From Beone Medicines Ltd.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Who owns it
Funds buying and selling- Reported value
- $9.9B
- Institutions reporting
- 280
- Shares held vs prior quarter
- ▲ 0.1%
- Positions opened / closed
- 41 / 41
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Baker Bros. Advisors LP | $2.5B | 8.8M | 25.3% | 0.0% |
| Primecap Management Co | $1.4B | 5.0M | 14.4% | ▲ 0.7% |
| Capital International Investors | $1.2B | 4.2M | 12.1% | ▲ 1.2% |
| FMR LLC | $706M | 2.5M | 7.1% | ▼ 32.9% |
| Capital World Investors | $641M | 2.2M | 6.5% | ▲ 38.6% |
| Citadel Advisors LLC | $406M | 1.4M | 4.1% | ▲ 38.1% |
| Temasek Holdings (Private) Ltd | $241M | 846K | 2.4% | ▼ 2.0% |
| Price T Rowe Associates Inc | $216M | 759K | 2.2% | ▲ 40.6% |
| Blackrock, Inc. | $198M | 695K | 2.0% | ▲ 5.6% |
| Millennium Management LLC | $155M | 543K | 1.6% | ▲ 165.2% |
| Morgan Stanley | $142M | 497K | 1.4% | ▲ 7.1% |
| Siren, L.L.C. | $133M | 465K | 1.3% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Beone Medicines Ltd.'s complete shareholder register. Values are as reported by the filers ; 4 inconsistently scaled filing rows were excluded.
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $391M 213 trades by 12 insiders · 96% under pre-set plans
Net ▼ $391M net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Wang Xiaodong Director | October 27, 2026 | Sell pre-set plan | 6,903 | $366.22 | $2.5M |
| Wang Xiaodong Director | October 27, 2026 | Sell pre-set plan | 3,965 | $365.43 | $1.4M |
| Wang Xiaodong Director | October 27, 2026 | Sell pre-set plan | 2,841 | $363.95 | $1M |
| Wang Xiaodong Director | October 27, 2026 | Sell pre-set plan | 8,148 | $363.24 | $3M |
| Wang Xiaodong Director | October 27, 2026 | Sell pre-set plan | 2,331 | $362.35 | $844,639 |
| Wang Xiaodong Director | October 27, 2026 | Sell pre-set plan | 320 | $360.64 | $115,404 |
| Wang Xiaodong Director | October 27, 2026 | Sell pre-set plan | 1,280 | $359.72 | $460,444 |
| Wang Xiaodong Director | October 27, 2026 | Sell pre-set plan | 1,681 | $358.75 | $603,052 |
| Wang Xiaodong Director | October 27, 2026 | Sell pre-set plan | 1,239 | $357.54 | $442,990 |
| Wang Xiaodong Director | October 27, 2026 | Sell pre-set plan | 1,440 | $355.62 | $512,087 |
| Wang Xiaodong Director | October 27, 2026 | Sell pre-set plan | 880 | $355.56 | $312,892 |
| Wang Xiaodong Director | October 13, 2026 | Sell pre-set plan | 1,260 | $353.24 | $445,078 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
- August 26, 2026
- August 5, 2026
- May 6, 2026
- April 14, 2026
- February 26, 2026
- November 6, 2025
Recent SEC filings
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Beone Medicines Ltd. in brief
- What does Beone Medicines Ltd. do?
- Beone Medicines Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Beone Medicines Ltd.'s stock ticker?
- Beone Medicines Ltd. trades under the ticker ONC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Beone Medicines Ltd.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Baker Bros. Advisors LP, Primecap Management Co and Capital International Investors. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Beone Medicines Ltd. stock?
- Over the last 12 months, Beone Medicines Ltd.'s directors and officers reported 0 open-market purchases and 213 sales on Form 4. The insider trading page charts every trade.
- When is Beone Medicines Ltd.'s next earnings date?
- Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Beone Medicines Ltd. announces its own schedule.
Follow research on Beone Medicines Ltd.
New research on the companies we cover arrives in the weekly email. Free, one email a week.